Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Chinese approval for bronchial thermoplasty system

Boston Scientific : 28 October, 2013  (New Product)
Alair bronchial thermoplasty system to be used in China for the treatment of patients with severe asthma
Chinese approval for bronchial thermoplasty system


Boston Scientific has received China Food and Drug Administration approval for the Alair Bronchial Thermoplasty System, an innovative medical device designed to treat severe asthma.  Expected to be available in the China market later this year, the Alair System provides a unique and effective therapy for patients with severe asthma which is not well controlled with inhaled corticosteroids and long-acting beta-agonists.



Bronchial Thermoplasty (BT) is a bronchoscopic procedure typically performed under moderate sedation on an outpatient basis.  Delivered by the Alair System, BT uses mild heat to reduce the excessive smooth muscle tissue in the airways.  This reduces airway constriction during an asthma attack, making attacks less frequent and less severe.



"We are delighted to see that the Boston Scientific Alair Bronchial Thermoplasty System has been officially certified by the China Food and Drug Administration," said Warren Wang, vice president and managing director-China, Boston Scientific.   "Unlike conventional treatments, Bronchial Thermoplasty offers a viable new option for patients suffering from severe asthma thanks to its breakthrough technology and mechanism of action. We believe this device can markedly improve the quality of life of asthma patients here in China."



BT delivered by the Alair System has been proven in clinical trials to be safe and effective. Data from the Asthma Intervention Research 2 (AIR2) Trial, a multi-site, double-blind, sham-controlled study, demonstrated that after undergoing BT treatment, patients reported significant improvement in asthma-related quality of life.1 Furthermore, the benefit of a single BT treatment performed over three bronchoscopy sessions was shown to persist out to at least five years.2



Key findings from the AIR2 Trial reported at five years include:



* Reduction in the percentage of BT-treated patients experiencing severe exacerbations (compared to patients treated with a sham control) was maintained out to five years

* Over five years, 48 percent average decrease observed in the rate of severe exacerbations in BT-treated patients compared to the year prior to receiving BT

* Over five years, 88 percent average decrease observed in the rate of emergency room (ER) visits for respiratory symptoms in BT-treated patients compared to the year prior to receiving BT

* High resolution computed tomography (HRCT) review showed no structural changes in the airways due to BT that were clinically significant

* No increase in hospitalizations, asthma symptoms, or respiratory adverse events over 5 years.


Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo